Cannabis Law Report

DECEMBER 15, 2021

A number of clinical trials have been investigating the potential of psychedelics in mental health treatment. “I agree with the committee that the preliminary findings from clinical trials — although still in early phases — evaluated by the panel are promising,” the decision’s author said.

Clinical Trials 52

Clinical Trials Conditions Supply Chain Environment 52

Cannabis Law Report

SEPTEMBER 8, 2021

Key Transaction Details: The Valens Company, a leading Canadian manufacturer of cannabis products, has entered into a long-term partnership with Epsilon, for exclusive access to the Epsilon’s GMP Manufacturing Facility in Southport , Queensland Australia (the “ Southport Facility ‘).

Access 97

Access Research and Development Medicine THC 97

Cannabis Law Report

AUGUST 17, 2021

Ganaxolone was generally well-tolerated with somnolence reported as the most common adverse event, consistent with previous trials; in addition, one treatment-related serious adverse event of seizure was reported in the trial. The live webcast can be accessed here and on the investor page of Marinus’ website.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

JULY 24, 2021

The groundbreaking progress that we’ve seen from the Multidisciplinary Association for Psychedelic Studies (MAPS) in its Phase 3 clinical trials of MDMA-assisted psychotherapy for Post-Traumatic Stress Disorder (PTSD), including receiving Breakthrough Therapy Designation from the Food and Drug Administration (FDA), shows great promise to date.

Research and Development 105

Research and Development Clinical Trials Therapy Events 105

NORML

OCTOBER 21, 2019

The agency in 2016 first announced its intent to license private entities to grow cannabis for FDA-approved clinical trials. The Court’s order permits petitioners to return to the Court of Appeals “in the event” that DEA engages in “significant delays” in the future.

DEA 104

DEA Cultivation Clinical Trials Policy 104

Cannabis Law Report

AUGUST 12, 2021

11, 2021 (GLOBE NEWSWIRE) COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the second quarter 2021 and gave an update on recent progress across its business. LONDON, Aug. Business highlights.

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Cannabis Law Report

MAY 29, 2022

The grand opening event and reception invited investors, stakeholders and the residents of Princeton to take a tour through the facilities. The psilocybin mushrooms are headed to clinical trials, drug companies and medical facilities. “I’m Without that approval, using psilocybin is currently illegal.

Research and Development 52

Research and Development Clinical Trials Medicine Access 52

Veriheal

MAY 3, 2022

a necessary question to address as medical marijuana becomes more accessible. Clinical Trial Sample Size. The trial was conducted with just 186 participants, which is far too small of a sample size to provide findings generalizable to the larger population.

Research and Development 98

Research and Development Clinical Trials Consumption Patients 98

Cannabis Law Report

SEPTEMBER 22, 2021

Access to Canopy Growth’s cannabinoid library including 335 derivatives and 14 patent families. Accelerated timelines to clinical trials and expansion of drug development pipeline. Phase 1 clinical trials are scheduled for Q3 2022 with Phase 2 trials expected in Q2 2023. the CBD, CBG or THC compounds).

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Cannabinoids 52

Cannabis Law Report

JANUARY 12, 2022

As Oregon prepares to roll out the nation’s first legal psilocybin-assisted services program, there is a recognized need for the community to track adverse events and measure efficacy. NPA’s mission is to ensure all Americans get the support they need to safely access psychedelic-assisted care. ABOUT MAYA.

Research and Development 52

Research and Development Therapy Safety Clinical Trials 52

Cannabis Law Report

JUNE 8, 2021

This SRA will leverage four other clinical trials being planned by the university, to determine the effects of psilocybin on inflammatory markers of patients who have exhibited Parkinson’s, Bipolar disorder, and chronic back pain. The goal at TrPR is to accelerate progress towards impactful and accessible psychedelic treatments.

Patients 92

Patients Research and Development Clinical Trials Chronic Pain 92

Cannabis Law Report

SEPTEMBER 14, 2021

13, 2021 /PRNewswire-PRWeb/ — A host of scientific research and clinical trials around the world are affirming the remarkable effectiveness of psilocybin, the principal psychoactive component of “magic mushrooms,” in the treatment of a variety of medical conditions, including depression, anxiety, addiction, and PTSD.

Clinical Trials 52

Clinical Trials Events Medicine Therapy 52

Cannabis Law Report

FEBRUARY 10, 2022

Congress passed the RTT Act in 2018 to give qualifying patients access to investigational drugs outside of a clinical trial setting. Psilocybin successfully completed an FDA-approved Phase 1 clinical trial in 2019, and two companies, COMPASS Pathways and Usona, both currently have Phase 2 trials ongoing.

DEA 52

DEA Clinical Trials Policy Research and Development 52

Cannabis Law Report

JULY 1, 2021

Clinical trials repeatedly demonstrate their promise for treating mood, anxiety, and substance use disorders. Access to Psychedelic Therapies and Equity in Emerging Psychedelics Industries. Clinical trials repeatedly demonstrate their promise for treating mood, anxiety, and substance use disorders. Background.

Law 59

Law Policy Research and Development Clinical Trials 59

SpeedWeed

JULY 6, 2021

By analyzing social, legal, and political barriers to access in this context, we hope to advance the understanding of their potential impact as therapeutics.”. The project also intends to advance research into how psychedelics can heal trauma and how to ensure equitable access to these therapies.

Policy 52

Policy Law Research and Development Therapy 52

Cannabis Law Report

JULY 14, 2021

ImmunoFlex” ), today announced that it has completed and analyzed its clinical trial of 21 patients, aged 60 to 70 years. Forward-looking statements are statements that relate to future, not past, events. For more information, visit www.Chemistree.ca. SOURCE Chemistree Technology Inc.

Research and Development 105

Research and Development Clinical Trials Events Treatment 105

Cannabis Law Report

JANUARY 19, 2022

GMP psilocybin previously manufactured by Psygen personnel in collaboration with a licensed dealer using Psygen’s methods has already been used in clinical trials for development of therapeutic products. “A primary application for psychedelics is to support psychotherapy for treatment of mental health conditions.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Conditions 52

Cannabis Law Report

MARCH 2, 2020

The UK government has eased import restrictions on medicinal cannabis, but has admitted it needs to do much more to improve access for patients. It will continue to engage with medical associations and patients to build evidence, using trials in the UK to accelerate our understanding of how medicinal cannabis can benefit patients.

Medicine 59

Medicine Research and Development Clinical Trials Patients 59

Cannabis Law Report

JANUARY 4, 2022

“I am so very proud of all Anebulo has achieved over the past 18 months, including building out a highly effective team, securing new intellectual property protection, preparing and starting a proof-of-concept clinical trial, advancing regulatory discussions with the U.S.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Cannabinoids 52

Cannabis Law Report

DECEMBER 1, 2021

Because it can cross the blood-brain barrier and gain access to the central nervous system (CNS), MYMD-1 is also positioned to be a possible treatment for brain-related disorders. The Company believes that Supera-CBD is currently on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

SEPTEMBER 2, 2021

ADCL will serve as prime contractor with subcontractor CLEARED4’s health verification platform to be used for appointments, sample tracking, reporting, program management, and mobile access pass visibility. Food and Drug Administration (U.S. For Applied DNA: Investor contact: Sanjay M.

Clinical Trials 99

Clinical Trials Research and Development Therapy Collective 99

Veriheal

JULY 12, 2021

Fortunately, congressional committees are fighting for medical cannabis access for veterans , and states are beginning to take measures to address their veterans , but what is the latest in research and what can one expect? Let’s find out. . Combat-Related PTSD is Slightly Different From PTSD .

Treatment 104

Treatment Sleep Clinical Trials Data 104

Cannabis Law Report

JANUARY 13, 2020

commercial and government payors to ensure that appropriate patients have access to Epidiolex with as few restrictions as possible. Continue to explore CBDV in autism through a combination of open-label and investigator-led placebo controlled clinical trials with data from one or more of these programs in 2020. Work with U.S.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Cannabis Law Report

NOVEMBER 16, 2021

As cleared by the FDA, the primary endpoint of the Phase 2 double-blind, placebo-controlled clinical trial is to achieve a reduction in the circulating levels of tumor necrosis factor-alpha (TNF-?), tumor necrosis factor receptor I (TNFRI) and IL-6. MyMD Contact: Robert Schatz. 646) 421-9523. rschatz@mymd.com www.mymd.com.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

OCTOBER 12, 2021

Mary Hartnett, Director of Medical Services at Sarah Lawrence College, stated, “safeCircle was our choice given the convenience of its on-site sample collection process, access to high-sensitivity RT-PCR-based testing with rapid turnaround times, ability to scale with our needs, and capacity to ease our administrative burdens.

Programs 52

Programs Clinical Trials Research and Development Therapy 52

Cannabis Law Report

AUGUST 3, 2021

ADCL’s solution includes the use of subcontractor CLEARED4’s health verification platform for appointments, sample tracking, and value-add services of campus access management. FDA) or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S.

Clinical Trials 105

Clinical Trials Therapy Collective Research and Development 105

Cannabis Law Report

DECEMBER 7, 2021

While cannabidiol was associated with a reduction in reported seizure events (RR?=?0.59, A qualitative assessment suggests that medical cannabinoids might be associated with adverse mental events. In conclusion, cannabidiol is associated with clinical improvement in Dravet syndrome. 1.69, 95% CI [1.20–2.36]) 1), 95%CI [??1.39–(??0.60)])

Safety 52

Safety Cannabinoids Events Data 52

Veriheal

JUNE 7, 2021

Note: Veriheal does not support illegally consuming therapeutic substances like MDMA but acknowledges that it transpires because of the current illicit status of both, which we strive to change by advocating for research, legal access, and responsible consumption. Always consult a physician before attempting alternative therapies.

Therapy 92

Therapy Treatment Conditions Clinical Trials 92

Cannabis Law Report

NOVEMBER 23, 2021

Because it can cross the blood-brain barrier and gain access to the central nervous system (CNS), MYMD-1 is also positioned to be a possible treatment for brain-related disorders. Originally developed for autoimmune diseases, MYMD-1’s primary purpose is to slow the aging process, prevent sarcopenia and frailty, and extend healthy lifespan.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Chronic Pain 52

SpeedWeed

AUGUST 4, 2021

This event saw doctors and researchers from all over the world presenting the scientific and clinical studies surrounding the medical benefits of cannabis. . I want to be a part of the change that sees patients become able to access quality cannabis medicines and to change lives. Courtesy of Sharon Bentley. Where are you now?

Chronic Pain 52

Chronic Pain Research and Development Medicine Supply Chain 52

Cannabis Law Report

SEPTEMBER 20, 2021

KWC is the largest national chain of ketamine infusion clinics in the United States and will add to Delic’s existing portfolio of two clinics operated by Ketamine Infusion Centers in California and Arizona , cementing its position as the leading and largest health provider in the country.

Treatment 52

Treatment Media Research and Development Patients 52

Cannabis Law Report

JANUARY 5, 2022

Because it can cross the blood-brain barrier and gain access to the central nervous system (CNS), MYMD-1 is also positioned to be a possible treatment for brain-related neurodegenerative and neuroinflammatory disorders. 2 Goates et al. 3 Koon Yee-Lee et al. 4 [link].

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

TheAnswerPage

JANUARY 11, 2022

Some patients put faith in anecdotal reports or the encouraging results of observational studies, but anecdotal reports and observational studies are not double blind randomized controlled clinical trials and do not prove that a treatment is or is not effective. Available at: [link] Accessed 05 Dec. Le-Short C., Narouze S.N.

Patients 98

Patients Education Marijuana Therapy 98

The Cannigma

DECEMBER 12, 2022

Turning down activity in the DMN allows better access to new areas of the brain, which can boost creativity and improve problem solving. Clinical research: Research is focusing on 5-MeO-DMT use in depression and anxiety. As such, there have been numerous clinical trials using ketamine. This stage lasts for 8 to 20 hours.

History 119

History Microdosing Research and Development Clinical Trials 119

Cannabis Law Report

DECEMBER 21, 2021

This service is available to businesses, K-12 schools, universities, event venues, medical offices, hospitality groups, and more to facilitate the safe return of people to in-person environments. Yet, more than half of the people in the least developed countries lack access to electricity. DALRADA SUPPORTS WORLD INITIATIVES.

Research and Development 52

Research and Development Supply Chain Data Business 52

Cannabis Law Report

SEPTEMBER 24, 2019

We believe patients and physicians deserve access to rigorously tested and evaluated cannabis-based medicines, manufactured to the highest standards and approved by medicines regulators, and we are delighted to be the first to offer this solution to the epilepsy community.”. “The Forward-looking statements. All investor and media enquiries.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

JANUARY 20, 2022

Eleusis pioneers the development of psychedelic drug candidates in the life sciences space, with the goal of transforming psychedelics into broadly accessible medicines. Medicines and Healthcare products Regulatory Agency’s Innovative Licensing and Access Pathway (“ILAP”), offering the potential to accelerate time to market.

Therapy 52

Therapy Research and Development Business Access 52